HRS 2014 Roundup
The 2014 Heart Rhythm Society Scientific Sessions ended May 10 in San Francisco with a big study from Boston Scientific on the benefits of implantable cardioverter defibrillator remote monitoring, and data on a smartphone-enabled electrocardiogram and the use of a spinal stimulator for heart failure patients. Earlier in the meeting, data were reported on the success of pacemaker remote monitoring and other studies.
You may also be interested in...
Neuromodulation 2015: Innovation Expands Opportunities In Chronic Pain
In the market for neuromodulation devices, the largest opportunity is in the treatment of chronic pain, a condition that affects more than 1.5 billion people worldwide. Innovation is driving growth in this sector as companies develop next-generation neuromodulation technologies designed to improve outcomes, and resolve some of the problems with existing devices; these technologies will significantly expand the treatable population, and will allow companies both large and small to capture market share based on device efficacy and the strength of clinical evidence.
Will Watchman Prevail With FDA? Boston Scientific’s LAA Closure Trial Raises Questions, Controversy
The PREVAIL study of Boston Scientific’s Watchman left atrial appendage (LAA) closure device was primarily positive, but will it be enough to win FDA approval for the device?
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.